This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 115/25/3197    most recent CIRCULATIONAHA.106.657981v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Satoh, M. Articles by Liao, J. K. Search for Related Content PubMed PubMed Citation Articles by Satoh, M. Articles by Liao, J. K. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Cardiomyopathy Heart Failure Hazardous Substances DB ESTRADIOL HYDROGEN PEROXIDE Related Collections Contractile function Congestive Cardiovascular Pharmacology Animal models of human disease Apoptosis

(Circulation. 2007;115:3197-3204.)
© 2007 American Heart Association, Inc.

Molecular Cardiology

Inhibition of Apoptosis-Regulated Signaling Kinase-1 and Prevention of Congestive Heart Failure by Estrogen

Minoru Satoh, MD, PhD; Christian M. Matter, MD; Hisakazu Ogita, MD, PhD; Kyosuke Takeshita, MD, PhD; Chao-Yung Wang, MD; Gerald W. Dorn, II, MD; James K. Liao, MD

From the Vascular Medicine Research Unit (M.S., H.O., K.T., C.-Y.W., J.K.L.), Brigham and Women’s Hospital and Harvard Medical School, Cambridge, Mass; Cardiovascular Research, Institute of Physiology (C.M.M.), University of Zurich, and Cardiology, Cardiovascular Center (C.M.M.), University Hospital Zurich, Zurich, Switzerland; and Molecular Cardiovascular Research (G.W.D.), University of Cincinnati, Cincinnati, Ohio.

Correspondence to James K. Liao, MD, Brigham and Women’s Hospital, 65 Landsdowne St, Room 275, Cambridge, MA 02139. E-mail jliao{at}rics.bwh.harvard.edu

Received August 14, 2006; accepted April 20, 2007.

Background— Epidemiological studies have shown gender differences in the incidence of congestive heart failure (CHF); however, the role of estrogen in CHF is not known. We hypothesize that estrogen prevents cardiomyocyte apoptosis and the development of CHF.

Methods and Results— 17ß-Estradiol (E2, 0.5 mg/60-day release) or placebo pellet was implanted subcutaneously into male Gq transgenic (Gq) mice. After 8 weeks, E2 treatment decreased the extent of cardiac hypertrophy and dilation and improved contractility in Gq mice. E2 treatment also attenuated nicotinamide adenine dinucleotide phosphate oxidase activity and superoxide anion production via downregulation of Rac1. This correlated with reduced apoptosis in cardiomyocytes of Gq mice. The antioxidative properties of E2 were also associated with increased expression of thioredoxin (Trx), Trx reductases, and Trx reductase activity in the hearts of Gq mice. Furthermore, the activation of apoptosis signal-regulating kinase 1 and its downstream effectors, c-Jun N-terminal kinase and p38 mitogen-activated protein kinase, in the hearts of Gq mice was reduced by long-term E2 treatment. Indeed, E2 (10 nmol/L)-treated cardiomyocytes were much more resistant to angiotensin II–induced apoptosis. These antiapoptotic and cardioprotective effects of E2 were blocked by an estrogen receptor antagonist (ICI 182,780) and by a Trx reductase inhibitor (azelaic acid).

Conclusions— These findings indicate that long-term E2 treatment improves CHF by antioxidative mechanisms that involve the upregulation of Trx and inhibition of Rac1-mediated attenuated nicotinamide adenine dinucleotide phosphate oxidase activity and apoptosis signal-regulating kinase 1 /c-Jun N-terminal kinase/p38 mitogen-activated protein kinase–mediated apoptosis. These results suggest that estrogen may be a useful adjunctive therapy for patients with CHF.

Key Words: apoptosis • antioxidants • heart failure • hormones

This article has been cited by other articles:

				E. A. Jankowska, P. Rozentryt, B. Ponikowska, O. Hartmann, D. Kustrzycka-Kratochwil, K. Reczuch, J. Nowak, L. Borodulin-Nadzieja, L. Polonski, W. Banasiak, et al. Circulating Estradiol and Mortality in Men With Systolic Chronic Heart Failure JAMA, May 13, 2009; 301(18): 1892 - 1901. [Abstract] [Full Text] [PDF]

				A. Maselli, P. Matarrese, E. Straface, S. Canu, F. Franconi, and W. Malorni Cell sex: a new look at cell fate studies FASEB J, April 1, 2009; 23(4): 978 - 984. [Abstract] [Full Text] [PDF]

				G. W. Dorn II Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling Cardiovasc Res, February 15, 2009; 81(3): 465 - 473. [Abstract] [Full Text] [PDF]

				W.-P. T Ruifrok, R. A de Boer, A. Iwakura, M. Silver, K. Kusano, R. A Tio, and D. W Losordo Estradiol-induced, endothelial progenitor cell-mediated neovascularization in male mice with hind-limb ischemia Vascular Medicine, February 1, 2009; 14(1): 29 - 36. [Abstract] [PDF]

				T. Ebrahimian, M. R. Sairam, E. L. Schiffrin, and R. M. Touyz Cardiac hypertrophy is associated with altered thioredoxin and ASK-1 signaling in a mouse model of menopause Am J Physiol Heart Circ Physiol, October 1, 2008; 295(4): H1481 - H1488. [Abstract] [Full Text] [PDF]

				A. Pedram, M. Razandi, D. Lubahn, J. Liu, M. Vannan, and E. R. Levin Estrogen Inhibits Cardiac Hypertrophy: Role of Estrogen Receptor-{beta} to Inhibit Calcineurin Endocrinology, July 1, 2008; 149(7): 3361 - 3369. [Abstract] [Full Text] [PDF]